A safety review showed that when fluoroquinolones were used systemically, they were associated with disabling and potentially permanent serious adverse effects.
A safety review showed that when fluoroquinolones were used systemically, they were associated with disabling and potentially permanent serious adverse effects.
A safety review showed that when fluoroquinolones were used systemically, they were associated with disabling and potentially permanent serious adverse effects.
The FDA finalized a rule extending its authority to all tobacco products, including e-cigarettes, cigars, hookah tobacco, and pipe tobacco, among others.
The FDA finalized a rule extending its authority to all tobacco products, including e-cigarettes, cigars, hookah tobacco, and pipe tobacco, among others.
The FDA finalized a rule extending its authority to all tobacco products, including e-cigarettes, cigars, hookah tobacco, and pipe tobacco, among others.
The FDA told manufacturers of a drug/device combination to treat schizophrenia they must provide more information before the product can be considered for approval.
The FDA told manufacturers of a drug/device combination to treat schizophrenia they must provide more information before the product can be considered for approval.
The FDA told manufacturers of a drug/device combination to treat schizophrenia they must provide more information before the product can be considered for approval.
